Bankmed

Image placeholder
Bankmed (2021-09)
  • Bankmed
  • Year : Sep 2021
3 Tokens
USD 300.00
Summary

Bankmed reported a very large net surplus of R668m in FY20 as low non-essential benefit utilisation caused atypically low claims frequency, in line with industry experience. We nevertheless expect earnings to progressively normalise over the medium term as the claims impact of COVID-19 subsides. In this regard, the net healthcare margin ranged between -1% and -3.5% between FY16 and FY19, and the net margin measured between 1% and 3%, with both metrics showing high stability.

Additional Information

The Stable Outlook reflects expectations that Bankmed’s earnings will normalise to historical ranges post COVID-19 and the scheme will continue to successfully balance affordability and targeted solvency margins, as has been demonstrated in the past. The rating could be upgraded if strategic initiatives to grow the membership base are successfully implemented and this leads to an improvement in the overall membership profile.

Related Publication

Discovery Health Medical Scheme (2018-05)

A Credit Rating report is a research report providing detailed analysis utilised by GCR in the accordance of a Credit Rating.

Credit Outlook on South African Medical Schemes Amidst The COVID-19 Pandemic

Despite potential earnings strain, GCR expects most rated schemes to remain resilient, given sufficient reserve buffers, although schemes with lowe...

GCR Risk Score Snapshot as of 19th July 2021

The GCR Ratings Framework is anchored upon the GCR Risk Score. This numerical scoring system, which forms a single analytical approach across multi...

Available Purchase Options: